These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 38917518)

  • 21. Phenotyping variants of tumefactive demyelinating lesions according to clinical and radiological features-A case series.
    Boyle T; Fernando SL; Drummond J; Fontes A; Parratt J
    Front Neurol; 2023; 14():1092373. PubMed ID: 36816572
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prognostic factors in Tumefactive demyelinating lesions: A retrospective study.
    Plowman RS; Varma H
    J Neurol Sci; 2021 Sep; 428():117591. PubMed ID: 34333380
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Imaging of Fulminant Demyelinating Disorders of the Central Nervous System.
    Razek AAKA; Elsebaie NA
    J Comput Assist Tomogr; 2020; 44(2):248-254. PubMed ID: 32195804
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [A case of pediatric multiple sclerosis presenting with a tumefactive demyelinating lesion].
    Majima H; Ito T; Koyama N
    Rinsho Shinkeigaku; 2017 Feb; 57(2):88-91. PubMed ID: 28132974
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Tumefactive demyelinating lesions of 15 patients: Clinico-radiological features, management and review of the literature.
    Sánchez P; Meca-Lallana V; Barbosa A; Manzanares R; Palmí I; Vivancos J
    J Neurol Sci; 2017 Oct; 381():32-38. PubMed ID: 28991707
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Gadolinium enhancement patterns of tumefactive demyelinating lesions: correlations with brain biopsy findings and pathophysiology.
    Kobayashi M; Shimizu Y; Shibata N; Uchiyama S
    J Neurol; 2014 Oct; 261(10):1902-10. PubMed ID: 25034274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The clinical spectrum of haemorrhagic CNS inflammatory demyelinating lesions.
    Hardy TA; Guo Y; Flanagan EP; Lucchinetti CF; Tobin WO
    Mult Scler; 2022 Oct; 28(11):1710-1718. PubMed ID: 35581949
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Tumefactive demyelination: an approach to diagnosis and management.
    Hardy TA; Chataway J
    J Neurol Neurosurg Psychiatry; 2013 Sep; 84(9):1047-53. PubMed ID: 23334629
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recurrent Fulminant Tumefactive Demyelination With Marburg-Like Features and Atypical Presentation: Therapeutic Dilemmas and Review of Literature.
    Vakrakou AG; Tzanetakos D; Argyrakos T; Koutsis G; Evangelopoulos ME; Andreadou E; Anagnostouli M; Breza M; Tzartos JS; Gialafos E; Dimitrakopoulos AN; Velonakis G; Toulas P; Stefanis L; Kilidireas C
    Front Neurol; 2020; 11():536. PubMed ID: 32714265
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Tumefactive demyelinating lesions: A comprehensive review.
    Algahtani H; Shirah B; Alassiri A
    Mult Scler Relat Disord; 2017 May; 14():72-79. PubMed ID: 28619436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Transtentorial herniation from tumefactive multiple sclerosis mimicking primary brain tumor.
    Vakharia K; Kamal H; Atwal GS; Budny JL
    Surg Neurol Int; 2018; 9():208. PubMed ID: 30488006
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Tumefactive demyelinating disease treated with decompressive craniectomy.
    Nilsson P; Larsson EM; Kahlon B; Nordström CH; Norrving B
    Eur J Neurol; 2009 May; 16(5):639-42. PubMed ID: 19309337
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Demyelination as a harbinger of lymphoma: a case report and review of primary central nervous system lymphoma preceded by multifocal sentinel demyelination.
    Kvarta MD; Sharma D; Castellani RJ; Morales RE; Reich SG; Kimball AS; Shin RK
    BMC Neurol; 2016 May; 16():72. PubMed ID: 27206499
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Balo's concentric sclerosis: An atypical demyelinating disease in pediatrics.
    Arenas Vargas LE; Bedoya Morales AM; Rincón Carreño C; Espitia Segura OM; Penagos N
    Mult Scler Relat Disord; 2020 Sep; 44():102198. PubMed ID: 32531753
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical and radiological characteristics and outcomes of patients with recurrent or relapsing tumefactive demyelination.
    Pervin I; Ramanathan S; Cappelen-Smith C; Vucic S; Reddel SW; Hardy TA
    Mult Scler Relat Disord; 2024 Feb; 82():105408. PubMed ID: 38219394
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tumefactive demyelinating lesions (TDLs): A case series of clinicoradiological features.
    Jain RS; Khan I; Kandelwal K; Desai T
    Clin Neurol Neurosurg; 2017 Nov; 162():91-94. PubMed ID: 28987645
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tumefactive demyelinating lesions: Characteristics of individual lesions, individual patients, or a unique disease entity?
    Weinshenker BG
    Mult Scler; 2015 Nov; 21(13):1746-7. PubMed ID: 26362899
    [TBL] [Abstract][Full Text] [Related]  

  • 38. An uncommon illness with a rare presentation: neurosurgical management of ADEM with tumefactive demyelination in children.
    VanLandingham M; Hanigan W; Vedanarayanan V; Fratkin J
    Childs Nerv Syst; 2010 May; 26(5):655-61. PubMed ID: 19949803
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Analysis of pathological characteristics of acute and chronic cerebral tumefactive demyelinating lesions].
    Sun C; Liu J; Gui Q; Lu D; Qi X
    Zhonghua Yi Xue Za Zhi; 2014 Dec; 94(45):3557-61. PubMed ID: 25622833
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Tumefactive Demyelinating Lesions in a Patient with Multiple Sclerosis Developed two Days after the Injection of Rituximab.
    Moghadasi AN
    Acta Neurol Taiwan; 2020 Dec; 29(4)():124-127. PubMed ID: 34018172
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.